TXG 10x Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TXG

Price (delayed)

$54.6

Market cap

$6.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.53

Enterprise value

$6.11B

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin ...

Highlights
10x Genomics's revenue has increased by 7% YoY and by 3.8% from the previous quarter
The company's quick ratio fell by 32% YoY but it rose by 9% QoQ
The company's gross profit fell by 2.7% YoY but it rose by 2.4% QoQ
The company's net income has shrunk by 96% YoY and by 5% QoQ
TXG's EPS has dropped by 91% year-on-year and by 4.8% since the previous quarter
Sector: Healthcare
Industry: Health Information Services
Website: http://www.10xgenomics.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of TXG
Market
Shares outstanding
116.19M
Market cap
$6.34B
Enterprise value
$6.11B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.85
Price to sales (P/S)
11.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.39
Earnings
Revenue
$536.2M
EBIT
-$169.56M
EBITDA
-$135.92M
Free cash flow
-$125.01M
Per share
EPS
-$1.53
Free cash flow per share
-$1.08
Book value per share
$6.96
Revenue per share
$4.64
TBVPS
$8.53
Balance sheet
Total assets
$1.01B
Total liabilities
$211.65M
Debt
$102.04M
Equity
$802.39M
Working capital
$489.89M
Liquidity
Debt to equity
0.13
Current ratio
5.37
Quick ratio
4.5
Net debt/EBITDA
1.75
Margins
EBITDA margin
-25.3%
Gross margin
75.6%
Net margin
-32.5%
Operating margin
-33.2%
Efficiency
Return on assets
-17.3%
Return on equity
-22%
Return on invested capital
-24.7%
Return on capital employed
-18.8%
Return on sales
-31.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
2.63%
1 week
3.25%
1 month
5.69%
1 year
8.72%
YTD
49.84%
QTD
-2.13%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$536.2M
Gross profit
$405.4M
Operating income
-$178.2M
Net income
-$174.33M
Gross margin
75.6%
Net margin
-32.5%
TXG's operating income has dropped by 113% year-on-year and by 6% since the previous quarter
10x Genomics's operating margin has shrunk by 98% YoY and by 2.2% QoQ
The company's net income has shrunk by 96% YoY and by 5% QoQ
10x Genomics's net margin has shrunk by 83% YoY

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
7.85
P/S
11.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.39
TXG's EPS has dropped by 91% year-on-year and by 4.8% since the previous quarter
The P/B is 31% above the last 4 quarters average of 6.0
The stock's price to sales (P/S) is 28% more than its last 4 quarters average of 9.2
10x Genomics's revenue has increased by 7% YoY and by 3.8% from the previous quarter

Efficiency

How efficient is 10x Genomics business performance
The ROE has plunged by 98% YoY and by 5% from the previous quarter
TXG's ROA has plunged by 94% YoY and by 4.8% from the previous quarter
TXG's ROS has dropped by 89% year-on-year
The return on invested capital has declined by 23% year-on-year and by 6% since the previous quarter

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
The company's quick ratio fell by 32% YoY but it rose by 9% QoQ
The current ratio has contracted by 27% YoY but it has grown by 11% from the previous quarter
10x Genomics's debt is 87% lower than its equity
10x Genomics's debt to equity has increased by 8% QoQ
10x Genomics's debt has increased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.